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 Assessed the susceptibility of an Australian marsupial trypanosome to human serum 15 
  Used the blood incubation infectivity test (BIIT)  16 
 Trypanosoma copemani has the potential to be infective for humans 17 
 First report of a marsupial trypanosome being potentially infective to humans 18 




Trypanosoma copemani is known to be infective to a variety of Australian marsupials. 23 
Characterisation of this parasite revealed the presence of stercorarian-like life-cycle stages in 24 
culture, which are similar to T. rangeli and T. cruzi. The blood incubation infectivity test (BIIT) 25 
was adapted and used to determine if T. copemani, like T. cruzi and T. rangeli, has the potential 26 
to grow in the presence of human serum. To eliminate any effects of anticoagulants on the 27 
complement system and on human high density lipoprotein (HDL), only fresh whole human 28 
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blood was used. Trypanosoma copemani was observed by microscopy in all human blood 29 
cultures from day 5 to day 19 post inoculation (PI). The mechanism for normal human serum 30 
(NHS) resistance in T. copemani is not known. The results of this study show that at least one 31 
native Australian trypanosome species may have the potential to be infective for humans. 32 
 33 
Keywords: Trypanosome, BIIT, quokka, zoonosis, marsupial. 34 
35 
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1.0 Introduction 36 
 37 
Only a few trypanosome species are known to cause disease in mammals. These include 38 
the etiological agents of animal trypanosomiasis (T. congolense, T. vivax, T. brucei brucei, and 39 
T. evansi) and human African trypanosomiasis (T. b. rhodesiense and T. b. gambiense) as well as 40 
T. cruzi, which causes Chagas’s disease in the Americas (Hoare 1972). Trypanosoma rangeli has 41 
also been detected in humans but it is not considered to be pathogenic (Stevens and Brisse 42 
2004). Trypanosoma rangeli and T. cruzi share a large number of vertebrate reservoirs including 43 
animals in five orders: Edentata, Marsupialia, Carnivora, Rodentia and Primates (Guhl and 44 
Vallejo 2003).  45 
Trypanosoma brucei rhodesiense and T. b. gambiense are resistant to the cytotoxic action 46 
of normal human serum because they are resistant to the trypanosome lytic factors (TLFs) that 47 
are naturally present in the blood of all humans and primates (Milner and Hajduk 1999, Molina-48 
Portela Mdel, Lugli et al. 2005). Resistance to TLFs are conferred by the presence of the serum 49 
resistance associated gene (SRA) in T. b. rhodesiense (Xong et al., 1998; De Greef and Hamers, 50 
1994). In T. b. gambiense, an SRA-like protein that is specific to T. b. gambiense (TgsGP), has 51 
been shown to be essential for human serum resistance (Capewell et al., 2013).  The resistance 52 
of T. cruzi to human serum is based on resistance to the alternative complement pathway (ACP) 53 
(Cestari and Ramirez, 2010).  However, not all of the life-cycle stages of T. cruzi are resistant to 54 
direct serum lysis. For example, the epimastigote life-cycle stage derived from the vector’s gut is 55 
efficiently lysed in human serum but the trypomastigote and amastigote stages from the 56 
vertebrate host are not (Tomlinson and Raper 1998).  Trypomastigotes of T. cruzi resist lysis 57 
because they are able to prevent the initiation of the complement cascade by expression of 58 
complement system inhibitors (Joiner, daSilva et al. 1988). 59 
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The Blood Incubation Infectivity Test (BIIT) developed by Rickman and Robson, (1970) 60 
was originally designed to distinguish the human-infective T. b. rhodesiense from the non 61 
human-infective T. b. brucei. This test is based on the observation that non human-infective 62 
trypanosomes are lysed by human serum while human-infective trypanosomes resist lysis. 63 
Therefore, this test can provide a method to identify new species of trypanosome that are 64 
potentially human-infective (Turner, McLellan et al. 2004).  Trypanosoma copemani infects a 65 
wide variety of Australian marsupials including the critically endangered Gilbert’s potoroo 66 
(Potorous gilbertii), the common wombat (Vombatus ursinus), the koala (Phascolarctos 67 
cinereus), the brush-tailed bettong (Bettongia penicillata), southern brown bandicoot (Isoodon 68 
obesulus), tiger quoll (Dasyurus maculatus) and brush tail possum (Trichosurus vulpecula) 69 
(Noyes et al., 1999; Austen et al., 2009; McInnes et al., 2010; Paparini et al., 2011; Botero et al., 70 
2013; Thompson et al., 2013). Molecular and phylogenetic characterisation of T. copemani has 71 
shown that it is similar to T. cruzi (Noyes et al., 1999; Austen et al., 2009; Botero et al., 2013). 72 
Recently, the vector for T. copemani has been identified as a tick, (Ixodes sp.) (Austen et al., 73 
2011).  The present study was performed to determine the relative susceptibility of T. copemani 74 
to human serum. 75 
 76 
2.0 Materials and Methods 77 
 78 
2.1 Study site and sample collection 79 
 80 
A quokka (Setonix brachyurus) (Q2088), previously identified as positive for T. 81 
copemani by PCR was trapped at Two Peoples Bay (34° 58’S, 118°11’E) near Albany, Western 82 
Australia under Murdoch University animal ethics permit W2204/09 and Department of Parks 83 
and Wildlife permit number SC000767. The quokka was anaesthetised with isoflurane and 84 
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approximately 5 millilitres (mL) of blood was collected by venepuncture of the lateral caudal 85 
vein. Fifty microliters (μL) of blood were used for the BIIT test. The remainder of the blood was 86 
added to commercial blood storage tubes containing ethylene diamine tetra-acetic acid (EDTA) 87 
(Sarstedt, Australia) and stored at 4°C for a maximum of 14 days. Thin-blood smears were 88 
prepared from 10µL of blood and stained with Modified Wright’s stain using an automated slide 89 
stainer (Hematek, Bayer). The blood smears were examined at 200 magnification and the 90 
number of trypanosomes counted using a haemocytometer to determine the numbers of 91 
trypanosomes / mL of blood.  92 
 93 
2.2 DNA extraction 94 
 95 
Whole genomic DNA was extracted from both fresh blood samples and cultured 96 
trypanosomes using a MasterPure
TM
 DNA Purification Kit (Epicentre
®
 Biotechnologies, 97 
Madison, Wisconsin, U.S.A.) following the manufacturer’s instructions and the DNA stored at -98 
20 ºC until required.  99 
 100 
2.3 Molecular characterisation of T. copemani   101 
 102 
A 1,439 bp fragment of the 18S ribosomal RNA (rRNA) gene and a 841bp fragment of 103 
the GAPDH gene was amplified and sequenced as previously described (Austen et al., 2009; 104 
McInnes et al., 2010), to confirm that the trypanosomes isolated from quokka 2088 were T. 105 
copemani. Amplified products were purified using a QIAquick
®
 PCR Purification kit (Qiagen, 106 
USA) and sequenced directly. Sequencing reactions were performed using an ABI Prism Dye 107 
Terminator Cycle Sequencing Core kit (Applied Biosystems, USA).  108 
 109 
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2.4 In vitro human serum resistance: Blood Incubation Infectivity Test  110 
 111 
Serum prepared from fresh whole blood from healthy human volunteers was used during 112 
this experiment. The use of human subjects for this study was approved by Murdoch University 113 
human ethics committee (project number 2010/053). 114 
The BIIT assay was performed in triplicate using serum freshly prepared from the blood 115 
of five healthy human volunteers as the test samples (labelled HA, HB, HC, HD and HE) and 116 
from horse blood as the control samples (labelled H0A, H0B and H0C).  Five sets of Modified 117 
Sloppy Evans Medium (MSEM) (Noyes, Stevens et al. 1999), used for the growth of the 118 
trypanosomes following the BIIT challenge were made up with each sample of the homologous 119 
human blood (HuMSEM) along with three sets of horse blood MSEM (HoMSEM). The BIIT 120 
was performed by adding a 50 µL aliquot of fresh quokka blood (containing ~five 121 
trypanosomes) into separate tubes, each containing 250 μL of one of the five samples of fresh 122 
undiluted human serum, or horse serum. These tubes were then incubated in a water bath at 123 
37°C for 5 hours. The entire contents of each incubated tube were then added to individual tubes 124 
containing 1 mL of HuMSEM or HoMSEM, and incubated at room temperature in the dark for 125 
24 hours before examination.  In addition, a 50 μL control sample of fresh quokka blood was 126 
directly transferred into a HuMSEM and a HoMSEM without the initial incubation in serum, and 127 
incubated at room temperature in the dark. Microscopic examination of wet-smear preparations 128 
of the medium from each culture was performed every day at 200× and 400× magnification to 129 
detect the presence of motile trypanosomes. If trypanosomes were detected, Giemsa-stained thin 130 
blood smears were prepared for further microscopic examination.  131 
On day 14 when high numbers of motile trypanosomes were observed in HuMSEM, 100 132 
μL volumes of the culture (approx. 7.5 x 10
7 
organisms) were transferred into 1 mL of 133 
HuMSEM with a 0.5 mL overlay of RPMI 1640 supplemented with 10% horse serum, 1000IU / 134 
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mL of ICN penicillin and 10000MCG / mL of streptomycin. Cultures were incubated at 37ºC 135 
with 5% CO
2
 to mimic mammalian conditions and determine survival of T. copemani in liquid 136 
culture. 137 
 138 
2.5 Statistical analysis 139 
The relative rate of replication of T. copemani in HuMSEM and HoMSEM after the BIIT 140 
was assessed by performing triplicate counts on three human cultures (HA, HB, HC) and 1 horse 141 
culture (H0C) at several time points after inoculation using a hemocytometer counting chamber. 142 
Half of the minimum level of detection (300) was added to each of the triplicate counts of T. 143 
copemani in HuMSEM and HoMSEM after the BIIT and Log10 transformed.  The mean log-144 
transformed count was plotted against time for each of the 4 cultures (HA, HB, HC and H0C).  145 
Non-linear regression was performed on the log-transformed counts from each culture using the 146 
plateau followed by one phase association function in GraphPad Prism version 5.00 for 147 
Windows (GraphPad Software, San Diego, USA).  The counts recorded for the human serum 148 
culture HA on days 18 and 19 were omitted from the analysis to improve the goodness of fit.  149 
Outputs of the regression analysis include: day of initiation of exponential growth, maximum 150 
trypanosome density and replication rate and their 95% confidence intervals.  Values were 151 
considered significantly different if the 95% CI’s for each output variable from the regression 152 
analysis did not overlap. 153 
 154 
3.0 Results 155 
 156 
3.1 Microscopy 157 
 158 
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Blood from quokka 2088 contained approximately 100 trypanosomes per mL. The 159 
morphology of the trypanosomes detected in the blood smear was consistent with the 160 
trypomastigote life-cycle stage (Figure 1) (Hoare 1972).  161 
 162 
3.2 Molecular characterisation of T. copemani 163 
 164 
The identity of the trypanosome infecting quokka 2088 was confirmed as T. copemani 165 
(genotype B) using sequence analysis of both the 18S rRNA and GAPDH genes before and after 166 
the BIIT test. The 18S rRNA (1439bp) and GAPDH (841bp) gene sequences of the quokka 167 
trypanosome isolate were found to be 100% identical to reference T. copemani sequences both 168 
before and after the BIIT challenge, and therefore were deposited in the GenBank database 169 
under the accession numbers (18S rRNA) HQ267094 and (GAPDH) HQ267095. 170 
 171 
3.3 Blood Incubation Infectivity Test (BIIT) 172 
 173 
Trypanosoma copemani isolated from quokka 2088 multiplied successfully in MSEM 174 
containing either human or horse blood, after undergoing the BIIT. There was no significant 175 
difference in the time to initiation of exponential growth in cultures containing human blood or 176 
horse blood and trypanosomes were detected in all cultures by day 5. Plots of the log-177 
transformed counts of T. copemani in cultures containing serum from 3 humans and 1 horse are 178 
presented (Figure 2).  Motile T. copemani was also observed in both the control HuMSEM and 179 
HoMSEM inoculated with blood taken directly from the quokka. Unfortunately complete growth 180 
curves for T. copemani directly inoculated into HuMSEM and HoMSEM from infected blood 181 
were not possible due to the delayed detection of trypanosomes in the first 9 days. Numbers of 182 
trypanosomes / mL were however measured at several time points from day 10 (Figure 3) with T. 183 
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copemani shown to multiply at a slightly faster rate in HuMSEM at days 10, 12 and 14 184 
compared to the growth rate of T. copemani in HoMSEM. On day 17, the numbers of 185 
trypanosomes in HuMSEM dropped compared to that detected in HoMSEM (Figure 3).   186 
The first trypanosome life-cycle stages to be detected in both HuMSEM and HoMSEM 187 
post-BIIT were slender, rapidly moving trypomastigotes and thin epimastigotes (Figure 4a), with 188 
the former life-cycle stage being the most abundant. Larger epimastigotes and sphaeromastigotes 189 
(Figure 4b), were detected by day 10, but in fewer numbers than the trypomastigotes and 190 
epimastigotes. There were no obvious morphological differences between the epimastigote and 191 
trypomastigotes life-cycle stages seen following culture in either human or horse blood. 192 
Motile T. copemani was observed in the subcultures grown in human MSEM overlayed with 193 
RPMI that were incubated at 37°C.  Trypomastigotes were the most abundant life-cycle stage 194 
detected with similar morphology to the trypomastigotes observed in quokka blood (Figure 4c). 195 
 196 
4.0 Discussion 197 
 198 
This study is the first time that the susceptibility of an Australian mammalian 199 
trypanosome to human serum has been assessed.  Results from comparing the growth curves of 200 
T. copemani in cultures containing human and horse serum showed that there was no consistent 201 
effect on the trypanosome, attributable to either host species. Trypanosoma copemani was 202 
detected as early as day 5 after the BIIT challenge, compared to direct inoculation into either 203 
HuMSEM or HoMSEM, in which trypanosomes were first detected on day 10. This suggests a 204 
faster rate of multiplication with the addition of liquid serum allowing the trypanosomes to 205 
readily gain access to the required nutrients compared to the solidified blood agar medium. The 206 
use of solidified MSEM by Noyes et al. (1999) to detect novel trypanosome species isolated 207 
from the blood of a wombat and kangaroo shows similar findings with trypanosomes first 208 
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detected on days 13 and 20 respectively.  Overall the growth of T. copemani inoculated directly 209 
into HuMSEM and HoMSEM appeared to be similar with only a slight increase in multiplication 210 
observed initially in the HuMSEM. Molecular analysis of the 18S rRNA and GAPDH genes was 211 
conducted to confirm that the trypanosomes isolated from the blood of quokka 2088 were T. 212 
copemani.  213 
The BIIT is designed to enable the identification of potentially human infective 214 
trypanosomes. In previous studies (Rickman and Robson 1970, Hawking 1978), the BIIT 215 
protocol included inoculation of human serum-exposed trypanosomes into rats and mice to 216 
determine viability. Inoculation of rodents was not possible in the present study because early 217 
attempts to infect rodents with T. copemani were unsuccessful (Austen, unpublished data). The 218 
failure of rodents to demonstrate infectivity with T. copemani may have resulted in the lack or 219 
low prevalence of metacyclic trypanosomes within the singular inoculum at the time of 220 
infection. For example, for natural infections to occur, multiple bites are needed from Glossina 221 
spp. (Hoare, 1972). This may also be the case for T. copemani, which may require multiple 222 
inocula to establish infection within the host. The immune response of the host may have also 223 
overcome the singular inoculum of T. copemani, however future studies are required to confirm 224 
this and to also understand the infective stages of T. copemani and how they are transmitted. 225 
The in vitro methodology used in this study was adapted from a previous method 226 
(Tomlinson, Jansen et al. 1995), where an in vitro assay was used to analyse the human serum 227 
resistance of various T. brucei genotypes.  To reduce the likelihood of false positive results, only 228 
fresh whole human blood was used in this study to eliminate the potential effect an anticoagulant 229 
may have had on either the complement system or the human serum high density lipoprotein 230 
(HDL) trypanolytic factor.  This is important because it has been shown that lipoprotein lipase 231 
activity and the level of HDL in rats infected with T. b. gambiense were increased if heparin was 232 
administered parenterally, which caused a reduction in the number of trypanosomes in the rat 233 
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(Nishimura et al., 2005). Furthermore, in vitro culture of T. b. gambiense was inhibited by the 234 
addition of plasma from infected rats treated with heparin (Nishimura et al., 2005). In contrast, 235 
the commonly used anticoagulant EDTA was found to inhibit the trypanolytic reaction of normal 236 
human serum on T. congolense TC35U (Ferrante and Allison, 1985). This uncoated 237 
trypanosome is normally lysed by human serum but is resistant to lysis by human serum 238 
containing EDTA. In 2006, T. evansi was identified in a human patient that lacked 239 
Apolipoprotein L-1 (APOL1), a human specific protein that binds to HDL and together cause the 240 
osmotic swelling of T. brucei and eventual death (Vanhollebeke et al., 2006).  The potential role 241 
of APOL1 in the results of this study were not investigated because trypanolytic factors (TLFs), 242 
of which APOL1 is a major component, have been shown to have no effect on the replication of 243 
T. cruzi in an in vivo model (Samanovic et al., 2009).  This is important because T. copemani is 244 
closely related to T. cruzi both biologically and phylogenetically (Austen et al., 2009; McInnes 245 
et al., 2011).   246 
The low numbers of trypomastigotes (100 trypanosomes/mL of blood) detected in the 247 
quokka’s blood at the time of sampling resulted in exposure of only about five trypomastigotes 248 
to human serum in the BIIT and subsequent culturing in HuMSEM. The low inoculum is both 249 
representative of a natural challenge, and also ensures that any potential defence mechanisms 250 
present in the blood samples being used in the test are not overwhelmed by a large inoculum, 251 
giving a spurious apparent survival of trypanosomes. The low number of trypanosomes used in 252 
the present study is in contrast to both the large inocula of 2 x10
6
 T. congolense exposed to 50% 253 
NHS by Xong et al. (2002), and of 1x10
7
 T. b. brucei exposed to 25% NHS by Turner et al. 254 
(2004).  These studies also used diluted serum in contrast to the undiluted normal human serum 255 
used in the present study, which shows that T. copemani blood life-cycle stages have a high level 256 
of resistance to human serum. The low inoculum used in the present study may have accounted 257 
for the initial lag phase in growth, which prevented the detection of viable parasites in the first 258 
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four days of the BIIT.  Detection of T. copemani was first possible on day five, a time lag which 259 
may have allowed the parasites to efficiently multiply and adapt to the vector life cycle stages, 260 
given that their maintenance in vitro is a methodology used to mimic the conditions of the vector 261 
(Hoare 1972). 262 
The observation that T. copemani is able to survive in the presence of human serum is 263 
interesting but must be interpreted cautiously.  Survival of trypanosomes when subjected to the 264 
BIIT test is strongly correlated to pathogenicity, in studies of T. b. brucei (Rickman and Robson 265 
1970). In addition, T. lewisi for instance, which is considered a rodent trypanosome (Hawking 266 
1978) has been reported to infect humans on eight occasions (Lun, Reid et al. 2009). Similarly, 267 
T. evansi which is responsible for a widely distributed disease called ‘‘surra’’ in domestic and 268 
wild animals found in Asia, Africa, South America, and even Europe has been identified in 269 
humans on four occasions (Lun, Reid et al. 2009). However, survival in the BIIT test does not 270 
necessarily correlate with an ability to infect humans and cause disease.  Furthermore, the risk of 271 
human infection with T. copemani would require interaction between the marsupial hosts, their 272 
tick vector and susceptible humans. Trypanosoma copemani does however have a broad 273 
marsupial host range, and increasing human encroachment on marsupial habitats, where ticks 274 
coexist with their natural marsupial hosts, may increase the risk of humans becoming infected 275 
with T. copemani.  276 
The mechanism of resistance to NHS by T. copemani is unclear.  If the mechanism is 277 
similar to T. cruzi, then the trypomastigotes may be able to inhibit the assembly, or accelerate 278 
the decay of C3 convertase, the central enzyme of the complement cascade (Tomlinson and 279 
Raper 1998). Chronic, non-pathogenic infection in the quokka may be maintained by the 280 
production of antibodies, which render the trypomastigotes sensitive to lysis via the alternative 281 
complement cascade, as occurs in mammalian hosts infected with T. cruzi (Krautz, Kissinger et 282 
al. 2000).  There are significant morphological similarities between the life-cycle stages 283 
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observed in T. copemani cultures and blood smears compared to T. cruzi. Therefore, it should 284 
not be surprising that blood-stream trypomastigote stages of T. copemani are resistant to human 285 
serum.  This is because trypomastigotes and amastigotes of T. cruzi from the vertebrate host are 286 
resistant to direct serum lysis from the complement system and epimastigotes from the gut of the 287 
vector are resistant (Tomlinson and Raper 1998, Krautz, Kissinger et al. 2000). It has been 288 
shown that cultured trypomastigotes of T. cruzi can form into both extracellular and intracellular 289 
amastigotes, both of which are infective to human monocytes in vitro, and may help to maintain 290 
the T. cruzi mammalian life-cycle (Ley, Andrews et al. 1988).  Amastigote stages of T. copemani 291 
have been observed in culture and in quokka blood (Austen et al., 2014), and may contribute to 292 
the resistance of T. copemani to human serum lysis.  293 
It is tempting to draw bold conclusions from the results of this study that T. copemani, 294 
and possibly other Australian trypanosomes, represent an extensive and latent pool that could 295 
give rise to new emerging infectious diseases (EIDs).  Indeed, approximately 75% of EIDs that 296 
have affected human populations in the past 30 years have been zoonotic (Daszak, Epstein et al. 297 
2007).  In addition to T. copemani, Australian trypanosomes from kangaroos (H25), possums 298 
(Pseudocheirus peregrinus), woylies (Bettongia penicillata), a banded hare wallaby 299 
(Lagostrophus fasciatus) and boodies (Bettongia lesueur) have closer phylogenetic relationships 300 
with T. cruzi than T. copemani (Noyes et al., 1999; Paparini et al., 2011; Botero et al., 2013).  In 301 
addition, there are a small but significant number of atypical human infections with “animal” 302 
trypanosomes that raises the possibility that many human infections remain undiagnosed (Lun, 303 
Reid et al. 2009); Truc et al., 2013). Trypanosoma cruzi is principally a parasite of sylvatic 304 
animals and it did not undergo the prolonged period of co-evolution with humans experienced by 305 
the T. brucei group.  Humans became a host only when they became ‘available’ in the sylvatic 306 
life-cycle of T. cruzi ~9,000 years ago, which corresponds with the period when humans 307 
developed settled (rather than nomadic) populations. The presence of these sedentary 308 
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populations and their dwelling places altered the life-cycle of the vector, creating a new non-309 
sylvatic cycle and a new ‘human’ disease (Aufderheide, Salo et al. 2004).  Therefore, the 310 
observation that T. copemani is able to resist NHS is insufficient to conclude that it has 311 
significant zoonotic potential per se.  Rather, a more complex chain of events would have to 312 
occur to significantly alter the life-cycle of the parasite and its mammalian hosts.  It may also be 313 
possible that T. cruzi is unique in the trypanosome world in that the vector and sylvatic cycle 314 
contained the correct ingredients for establishment in the “human” domestic environment.  315 
Whilst the human population of Australia is unlikely to undergo a significant societal change 316 
equivalent to South America 9,000 years ago, Australians live in relatively close proximity to 317 
native marsupials and the level of exposure to marsupial-derived tick vectors is unknown.  It is, 318 
therefore possible that isolated cases of human trypanosomiasis may occur in the Australian 319 
population.  If this does occur, then information on the susceptibility of native trypanosomes to 320 
currently available trypanocidal drugs would be of enormous value. 321 
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Figure 1. Light photomicrograph of T. copemani in a Modified Wrights stained blood smear 446 
from a quokka. Scale bar represents 10µm. 447 
 448 
Figure 2. Mean log10-transformed count (plus half minimum detection level) of T. copemani 449 
grown in cultures containing serum from 3 humans (HA, HB, HC) and one horse (H0C).  The 450 
trend line represents the mean log-transformed count and markers () represent individual 451 
counts. 452 
Figure 3. Numbers of trypanosomes / mL measured at several time points after direct inoculation 453 
of infected quokka blood into HuMSEM and HoMSEM. 454 
 455 
Figure 4. Light photomicrographs of T. copemani grown in vitro, in a culture of blood from the 456 
quokka, which had undergone the blood incubation infectivity test. (A) Epimastigote (e) and 457 
trypomastigote (t) forms at day 10, in a Modified Wrights stained smear from HuMSEM. (B) 458 
Sphaeromastigotes (s), epimastigotes and trypomastigote forms at day 10, in a Modified Wrights 459 
stained smear from HuMSEM.  (C) Trypomastigote form of T. copemani at day 18, grown in 460 
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